The global melanoma market is anticipated to expand in value from US$ close to 5 Billion in 2016 to an estimated US$ 14 billion by 2024, representing a robust Compound Annual Growth Rate (CAGR) of 12%. The advancement in research and development of therapeutics, early entry and dominance of immunotherapeutics, strong investor base and a robust clinical pipeline ensures a bright future for the key players involved in the segment.
This report on the global malignant melanoma is based on an in-depth analysis of the current market trends, opportunities and other dynamics that may have a significant impact on the market. Special emphasis has been put on the collection and analysis of latest data that will influence the market in the present and the future. Further, analysis of sales data, patent expiry, Cost analysis of therapeutics and collaboration between industries has been used to devise an accurate and efficient projection regarding the future of malignant melanoma market which clearly indicates it to be a key market in the future of skin cancer therapy.
The targeted therapy segment of the malignant melanoma market is anticipated to be the most promising market of the future due to its high efficacy with minimum side effects. Further, sales analysis and future projections of existing therapeutics show exponential growth for the newly introduced biologics like Opdive and cotellic due to multifold increase in adoption rate, positive post marketing response and feedback from users.
The US currently leads the global malignant melanoma market due to large patient base, easy availability and affordability of the newly introduced biologics followed by Europe. Other regions such as Australia and New Zealand have also contributed significantly to the current market size. However, the increasing patient base in highly populated regions like China and India is estimated to shift the market size to these Asian regions by the year 2024.
Key Topics Covered
1. Malignant Melanoma – Common Cancer with High Mortality
1.1 Prologue to Malignant Melanoma
1.2 Risk Factors Associated with Melanoma
1.3 Overview of Melanoma Diagnosis & Therapy
2. Analysis Regarding the Global Prevalence of Melanoma
2.1 Prevalence in the US
2.2 Prevalence in Europe & Rest of the World
3. Melanoma Market Analysis by Diagnosis & Screening
3.1 Stages of melanoma Diagnosis & Treatment Options
3.2 Cost Analysis of Melanoma Screening
4. Malignant Melanoma Therapy & Cost Analysis by Stage
4.1 Stage 0
4.2 Stage I
4.3 Stage II Melanoma
4.4 Stage III Melanoma
4.5 Stage IV Melanoma
4.6 Recurrent Melanoma
5. Malignant Melanoma Management & Therapy – Cost Analysis by Treatment Modality
5.1 Surgery
5.2 Radiation Therapy
5.3 Chemotherapy
5.3.1 Decarbazine
5.3.2 Temozolomide
5.3.3 Taxol (Paclitaxel & Carboplatin)
5.4 Biological Therapy/Targeted Therapies
5.4.1 T-VEC (Imlygic)
5.4.2 Nivolumab (Opdivo)
5.4.3 Ipilimumab (Yervoy)
5.4.4 Pembrolizumab (Keytruda)
5.4.5 Peginterferon alpha 2-b (Sylatron)
5.4.6 Interleukin-2 (IL-2; Proleukin)
5.5 Inhibitors in Malignant Melanoma Treatment
5.5.1 Vemurafenib (Zelboraf) + Cobimetinib (Cotellic)
5.5.2 Dabrafenib (Tafinlar) + Trametinib (Mekinist)
5.5.3 Vemurafenib (Zelboraf)
6. Sales Analysis of Global Melanoma Therapeutics
6.1 Global- Melanoma Chemotherapy Drug Sales
6.2 Melanoma Targeted Therapy Sales Analysis
7. Malignant Melanoma Therapy – Market Trend & Scope Analysis
7.1 Overview – Screening & Traditional Therapy Market
7.2 Modern Melanoma Therapeutics Market
8. Global Malignant Melanoma Drug Clinical Pipeline Overview
9. Regional Analysis of the Melanoma Drug Market
9.1 North America
9.1.1 US
9.1.2 Canada
9.2 Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 Australia
9.4 Middle East & Africa (MEA)
10. Global Melanoma Drug Market Dynamics
10.1 Driving Factors of the Malignant Melanoma Drug Market
10.2 Restraining Factors of the Melanoma Drug Market
11. Future Forecast Regarding the Malignant Melanoma Drug Market
12. Global Malignant Melanoma Drug Clinical Pipeline by Company & Phase
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration
12.11 Registered
13. Marketed Malignant Melanoma Drug Clinical Insight
14. Competitive Analysis
14.1 AVAX Technologies
14.2 Biogen Idec
14.3 BioVex
14.4 Bristol-Myers Squibb
14.5 Chiron
14.6 Enzon Pharmaceuticals
14.7 GlaxoSmithKline
14.8 Lorus Therapeutics
14.9 Medarex
14.10 Merck
14.11 Ono Pharmaceutical
14.12 Plexxikon
14.13 Reliance Life Sciences
14.14 Roche
For more information about this report visit https://www.researchandmarkets.com/research/qsrm8n/global_melanoma?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-melanoma-market-report-2018—anticipated-to-reach-a-market-value-of-14-billion-by-2024-300633654.html
SOURCE Research and Markets
